Test saliva or blood markers to track kidney and leg disease treatment
Part of Heart & circulation, Kidney & urinary clinical trials.
This study looks at a gene marker (“lncRNA,” a natural molecule in the body) to see how well an oral absorbent, with or without probiotics, is helping people with chronic kidney disease (CKD) who also have blocked leg arteries. It may help doctors better measure treatment impact and tailor care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be over 20 years old when you are screened
- Have CKD with stable kidney function (eGFR between 15 and 60) for at least about a month
- Have symptoms of blocked leg arteries with moderate/severe staging (Rutherford stage 2 or higher) and an ankle test showing poor blood flow (ABI < 0.9)
- Be able to follow eating and stomach requirements (no active serious bleeding, and not in fasting/unable-to-eat situations)
- Not have had antibiotics or probiotics in the last 2 weeks, and be able to avoid them during the study
- Have acceptable blood and nutrition levels (albumin not too low, hemoglobin not too low, and no severe malnutrition or recent major bleeding)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an oral absorbent plus probiotics can improve gut health and circulation in people who have chronic kidney disease and symptomatic peripheral artery disease (PAD). It will also track changes in blood markers and how well blood vessels function.
This trial studies an oral product (a “uremic toxin” absorber) plus probiotics to help slow the progression of chronic kidney disease. It may help by lowering harmful gut-related substances that can build up when kidney function is reduced.
This trial tests if taking Xiqing (a Chinese herbal product) and probiotics together can help people with chronic kidney disease (CKD) by improving gut health and making their medication work better. It is for patients with moderate to advanced CKD who do not need dialysis yet.
This research study tests an experimental treatment for people with chronic kidney disease who are not yet on dialysis. The goal is to see if the treatment is safe and how it affects kidney function.
This trial tests if an oral medication that absorbs toxins plus probiotics can reduce inflammation and slow kidney damage in people with diabetes-related kidney disease (DKD). It may help those with mild to severe kidney function loss.
This trial tests whether taking a probiotic supplement can slow down the decline of kidney function in people with moderate chronic kidney disease (CKD stages 3 and 4). If you have stable kidney disease and are not already taking probiotics, joining this study could help researchers find a new way to protect your kidneys.
Hear when a new CKD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.